Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neflamapimod placebo-controlled proof-of-concept study in mild Alzheimer's disease
NL-OMON48874Phase 2Active, not recruiting
- Sponsor
- Worldwide Clinical Trials
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of neflamapimod in Alzheimer's disease (AD), sponsored by Worldwide Clinical Trials. Started May 2018; status: active, not recruiting.
02
Drugs
neflamapimod
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON48874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48874.